Richard Mulligan - 03 Mar 2022 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Role
Head of SanaX, Director
Signature
/s/ James J. MacDonald, Attorney-in-Fact for Richard Mulligan
Issuer symbol
SANA
Transactions as of
03 Mar 2022
Net transactions value
$0
Form type
4
Filing time
08 Mar 2022, 08:06:35 UTC
Previous filing
02 Jul 2021
Next filing
12 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SANA Stock Options (Right to Buy) Award $0 +250,000 $0.000000 250,000 03 Mar 2022 Common Stock 250,000 $5.70 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable as to 25% of the underlying shares on March 3, 2023 and in 36 equal monthly installments thereafter.